Últimas noticias sobre AIM ImmunoTech (AMEX:AIM) Bolsa

AIM ImmunoTech

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech Inc

Aimfinity Investment Corp I

Altra Industrial Motion Corp Com

Ainos Inc

Aimia Inc

AIMRITE HOLDINGS CORP by Aimrite Holdings Corporation

Aimrite Holdings Corp

AI / ML INNOVATIONS INC by AI / ML Innovations Inc.

AI/ML Innovations Inc

Immersed Inc

News

AIM ImmunoTech Receives Notice That It Is No Longer In Compliance With NYSE American Continued Listing Standards

Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders
In AIM's View, the Activist Group's Plan to Reimburse Individuals More Than $5 Million for Failed Attempts to Gain Control of the Board – Without Putting this to a Shareholder Vote – Is Grossly Irresponsible and Not in the Best Interests of All Shareholders
Reminds Shareholders that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Recommended Against Giving the Dissident Nominees Control of the AIM Board, Specifically Citing Their Lack of a Plan, Among Other Issues
Highlights Activist Group Nominees Todd A. Deutsch's and Robert L. Chioini's Checkered Pasts and Affiliations with Securities Law Criminals – and that Mr. Chioini Was Fired as CEO of Rockwell Medical for His "Sustained Mismanagement" and "Blatant Disregard for Shareholder Concerns"1
Questions How Activist Group Nominee Paul Sweeney Could Function as an Independent Director Given that Mr. Kellner is Apparently the Biggest Investor in Mr. Sweeney's Private Equity Firm
AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) ("AIM" or the "Company") today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders (the "Annual Meeting"), presently scheduled for December 17, 2024:
With the Annual Meeting quickly approaching, it is critical that shareholders vote on the WHITE universal proxy card to re-elect all four current members of our Board of Directors (the "Board"). As shareholders consider this important decision, we ask that they keep the following in mind:

Management

Aim ImmunoTech Urges Shareholders To Vote On The White Universal Proxy Card "For" All 4 Incumbent Board Members; Believes Future Of The Co And That The Current Board Is Best Positioned To Continue Clinical Trial Momentum, Commercialize Ampligen And Deliver Long-Term Value For Shareholders

Legal

AIM ImmunoTech Announced It Was Granted Patent No. 2,0832,813 Covering Ampligen For Use In Treatment Of Post-COVID Condition Of Fatigue

Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) with a Buy and lowers the price target from $5 to $4.5.

Price Target

Analyst Ratings

Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $4.5

ISS Finds That Activist Group's Plan is "Limited" and Does Not Justify Control of the Board
ISS Notes Activist Group Nominee Robert L. Chioini "Does Not Appear to Be an Appropriate Choice for the AIM Board" Given His Track Record at Rockwell Medical and Ties to Securities Law Felons
ISS Also Recommends Against Election of Activist Group Nominee Todd A. Deutsch
AIM Highlights $15 Million+ Investment Partnership Between Activist Group Nominees Ted Kellner and Paul Sweeney – Meaning They Are Not Independent of One Another
Company Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates on the WHITE Universal Proxy Card and Discarding Any Proxy Materials Received from the Activist Group
AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) ("AIM" or the "Company") today announced that independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that shareholders vote "FOR" Company nominees Nancy K. Bryan and Dr. William M. Mitchell at the upcoming 2024 Annual Meeting of Stockholders (the "Annual Meeting"), presently scheduled for December 17, 2024.

ISS Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan And Dr. William M. Mitchell; ISS Finds That Activist Group's Plan Is "Limited" And Does Not Justify Control Of The Board

Kellner Group Has Financial Resources AIM Needs
Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders
AIM Cash Conservation Plan is Too Little Too Late, Exposes Desperate Financial Condition
AIM Stock Price has Declined 99+%
Frantic AIM Board Doubles Down on Attempts to Deceive Stockholders
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we" or "us" and, as nominees, the "Kellner Group Nominees") today issue the following press release in connection with their efforts to bring accountability to the entrenched, incumbent Board of Directors of AIM Immunotech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>).

Kellner Group Urges Stockholders Of AIM Immunotech To Vote The Gold Card; Says "Kellner Group Has Financial Resources AIM Needs; Kellner Group Owns 5.04% Of Outstanding Shares And Is Fully Aligned With Stockholders"

Highlights Activist Group's Nominees' Checkered Backgrounds, Skewed Incentives and Lack of Independence
Warns AIM Shareholders of Activist Group's Plan to Reimburse Individuals More Than $5 Million for Failed Litigation Against AIM, in Addition to Any Expenses Incurred in Connection With This Year's Proxy Contest
Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials Received from the Activist Group
AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) ("AIM" or the "Company") today issued a presentation highlighting why shareholders should NOT elect the four director candidates nominated by a group of activist investors (collectively, the "Activist Group") as part of their multi-year attempt to take over AIM's Board of Directors (the "Board") at the upcoming 2024 Annual Meeting of Stockholders (the "Annual Meeting"), presently scheduled for December 17, 2024.

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group's Nominees To The Board; Highlights Activist Group's Nominees' Checkered Backgrounds, Skewed Incentives And Lack Of Independence

Sets Record Straight on Mischaracterization of AIM's Historical Share Price
Reminds AIM Shareholders of Activist Group's Numerous Lies, Omissions and Misrepresentations in Multi-Year Effort to Take Control of the Board
Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials Received from the Activist Group
AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) ("AIM" or the "Company") today issued the following statement refuting the false and misleading claims recently made by a group of activist investors (collectively, the "Activist Group") relating to their multi-year attempt to take over AIM's Board of Directors (the "Board") at the upcoming 2024 Annual Meeting of Stockholders (the "Annual Meeting"), presently scheduled for December 17, 2024.
Since 2016, the Board and management team have worked to overcome multiple obstacles, refocus the Company's clinical development programs to high-value indications, improve its financial condition and lay the foundation for long-term shareholder value creation. To be clear, the Board and management are unhappy with the Company's stock price performance – but they are doing everything possible to continue the significant momentum with Ampligen – which is ultimately what will create long-term value for all shareholders.

AIM ImmunoTech Refutes Activist Group's False And Misleading Claims; Urges Shareholders To Safeguard Aim By Voting "For" All Of The Board's Incumbent Candidates And Discarding Any Proxy Materials Received From The Activist Group

Aim Immunotech Announced Cash Conservation Plan; Independent Board Members To Receive 100% Of Director Compensation In Aim Stock

Highlights How Positive Data in AIM's Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic Cancer
Warns Shareholders of Its Belief that the Activist Group and Its Nominees Have a Self-Interested Agenda and Could Put AIM's Clinical Progress at Risk
Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials from the Activist Group
Shareholders Can View and Download the Presentation <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmunotech.s3.us-west-1.amazonaws.com%2FAIM%2BInvestor%2BPresentation%2B%28November%2B2024%29.pdf&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=Here&amp;index=1&amp;md5=aebd9987f2d8525d889b11917beb3e81">Here</a>
AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) ("AIM" or the "Company") today issued a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmunotech.s3.us-west-1.amazonaws.com%2FAIM%2BInvestor%2BPresentation%2B%28November%2B2024%29.pdf&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=presentation&amp;index=2&amp;md5=f3ad08194b4528269f1b5432d10f7266">presentation</a> in connection with its upcoming 2024 Annual Meeting of Stockholders the ("Annual Meeting"), presently scheduled for December 17, 2024.
Highlights of the presentation include the following:
<ul>
<li>AIM is executing on its strategy to create long-term value for patients and shareholders by driving clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space.</li>
<li>AIM's clinical pipeline has significant momentum and is laying the groundwork for commercialization opportunities by delivering exciting data across clinical trials, including in two ongoing studies with AstraZeneca and Merck. These commercialization opportunities are what can drive substantial value creation.</li>
<li>If elected, the Activist Group intends to seek over $5 million from AIM to pay for its previous takeover attempts and litigation against the Company that the Activist Group lost, in addition to any expenses incurred in connection with its solicitation for this year's Annual Meeting. The Activist Group disclosed that it does notintend to put this personal reimbursement to a shareholder vote.</li>
<li>Despite AIM's best attempts at a constructive settlement that would put two of the Activist Group's nominees on the Board, the Activist Group has continued to insist it receive upwards of $8 million to make all litigants whole in connection with certain litigation as part of any resolution – this represents more than 50% of AIM's current market capitalization.</li>
<li>The Activist Group has indicated it would likely appoint Robert Chioini as interim CEO while the Board runs a succession process should its nominees gain control of the Board. Mr. Chioini was fired as CEO of Rockwell Medical in 2018 because of his "sustained mismanagement" of the company and "blatant disregard for shareholder concerns," according to a Rockwell Medical spokesperson.1 Following his termination, Mr. Chioini "refuse[d] to accept the decision" and, without authorization, filed a Current Report on Form 8-K on the company's behalf "making various assertions regarding the five independent directors who voted in favor of Mr. Chioini's removal."2This behavior indicates, in our view, that Mr. Chioini is unfit to serve as a public company director – let alone CEO.</li>
</ul>

AIM ImmunoTech Issues Presentation Detailing Case For Re-Electing Current Directors To Oversee Continued Momentum And Drive Strategy To Create Long-Term Value For Patients And Shareholders; Warns Shareholders Of Its Belief That The Activist Group And Its Nominees Have A Self-Interested Agenda And Could Put AIM's Clinical Progress At Risk

Insider Trades

SEC Form 4 Filing Shows AIM ImmunoTech CEO And Director Thomas K. Equels Purchases 85,000 Shares At An Average Price Of $0.20

AIM ImmunoTech Form4 Filing Shows CEO And President Thomas K Equels Bought 60,110 Shares At An Average Price Of $0.18/Share

General

AIM ImmunoTech shares are trading higher after the company announced the publication of Phase 1 data from its Roswell Park study on Ampligen in early-stage triple-negative breast cancer.

Biotech

AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer

<a href="https://www.roswellpark.org/newsroom/202411-roswell-park-clinical-trial-points-toward-promising-new-therapy-most-aggressive" title="https://www.roswellpark.org/newsroom/202411-roswell-park-clinical-trial-points-toward-promising-new-therapy-most-aggressive">https://www.roswellpark.org/newsroom/202411-roswell-park-clinical-trial-points-toward-promising-new-therapy-most-aggressive</a>

Roswell Park's Phase 1 Trial Results For Triple-Negative Breast Cancer, With 66% Achieving Complete Or Near-Complete Remission And No Immune-Related Adverse Events; Findings Published In Journal For ImmunoTherapy Of Cancer

AIM ImmunoTech shares are trading higher after the company reported better-than-expected Q3 EPS results.

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.12) by 50 percent. The company reported quarterly sales of $35.00 thousand which missed the analyst consensus estimate of $67.50 thousand by 48.15 percent. This is a 23.91 percent decrease over sales of $46.00 thousand the same period last year.

Earnings

AIM ImmunoTech Q3 2024 GAAP EPS $(0.06) Beats $(0.12) Estimate, Sales $35.00K Miss $67.50K Estimate

<h3>Companies Reporting Before The Bell</h3>
• Sigma Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGML#NASDAQ">SGML</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $72.08 million. 
• Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) is projected to report quarterly loss at $0.54 per share on revenue of $16.50 million. 
• Digihost Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGHI#NASDAQ">DGHI</a>) is projected to report quarterly loss at $0.13 per share on revenue of $9.90 million. 
• Aegon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEG#NYSE">AEG</a>) is projected to report earnings for its third quarter. 
• Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) is expected to report earnings for its third quarter. 
• WiSA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) is likely to report quarterly loss at $0.68 per share on revenue of $1.00 million. 
• AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is likely to report quarterly loss at $0.10 per share on revenue of $20 thousand. 
• Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $87.84 million. 
• RLX Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $105.08 million. 
• Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) is projected to report quarterly earnings at $2.10 per share on revenue of $33.95 billion. 
• Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) is estimated to report quarterly earnings at $1.02 per share on revenue of $746.54 million. 
<h3>Companies Reporting After The Bell</h3>
• Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) is likely to report earnings for its third quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BABA

BPTH

DGHI

NEXN

NGNE

SGML

TRIB

WISA

Earnings Scheduled For November 15, 2024

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) will release its quarterly earnings report on Friday, 2024-11-15. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate AIM ImmunoTech to report an earnings per share (EPS) of $-0.10.
The market awaits AIM ImmunoTech's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.09, leading to a 5.88% increase in the share price the following trading session.
Here's a look at AIM ImmunoTech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.15</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>-0.12</td>
<td>-0.26</td>
<td>-0.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>3.0%</td>
<td>6.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731592849_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of AIM ImmunoTech were trading at $0.242 as of November 13. Over the last 52-week period, shares are down 46.1%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AIM/earnings">To track all earnings releases for AIM ImmunoTech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into AIM ImmunoTech's Upcoming Earnings

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-08-14. Here's what investors need to know before the announcement.
Analysts estimate that AIM ImmunoTech will report an earnings per share (EPS) of $-0.12. 
Anticipation surrounds AIM ImmunoTech's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.01, which was followed by a 3.33% increase in the share price the next day.
Here's a look at AIM ImmunoTech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.15</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>-0.12</td>
<td>-0.26</td>
<td>-0.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>3.0%</td>
<td>6.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731002593_0.png" alt="eps graph" />
<h3>Market Performance of AIM ImmunoTech's Stock</h3>
Shares of AIM ImmunoTech were trading at $0.2498 as of November 06. Over the last 52-week period, shares are down 40.31%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/AIM/earnings">To track all earnings releases for AIM ImmunoTech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring AIM ImmunoTech's Earnings Expectations

Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney iss...

Kellner Group urges AIM ImmunoTech stockholders to vote for its nominees

Kellner Group urges AIM ImmunoTech shareholders to vote the Gold card

Kellner Group announces former CEO to join SAB if nominees elected

AIM ImmunoTech (AIM) announced that independent proxy advisory firm Glass, Lewis & Co., LLC has recommended that shareholders vote "FOR" company no...

AIM ImmunoTech says Glass Lewis recommends shareholders vote for nominees

Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert Chioini and Paul Sweeney issued a ...

Kellner Group says former AIM ImmunoTech executive supports nominees

AIM ImmunoTech (AIM) announced that the Netherlands Patent Office has granted Patent No. 2,032,813 – a compositions and methods patent – covering A...

AIM ImmunoTech expands patent portfolio with new Netherlands patent

AIM Immunotech receives non-compliance notice from NYSE American

AIM ImmunoTech (AIM) announced that it received a notice from the NYSE American, notifying the company that it is no longer in compliance with NYSE...

AIM ImmunoTech receives noncompliance notification from NYSE

An announcement from AIM ImmunoTech ( ($AIM) ) is now available. AIM ImmunoTech announced that Thomas K. Equels and Peter W. Rodino III have decide...

AIM ImmunoTech Executives Forego Bonuses for R&D Focus

Press Releases

Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell

AIM's Clinical Strategy Under Incumbent Board Has Totally Failed

Kellner Group Announces Support from Another Former AIM Senior Executive

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

Comments

AIM ImmunoTech

Noticias

Últimas noticias sobre AIM ImmunoTech (AMEX:AIM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL